Miromatrix Medical, Inc. (MIRO)
| Market Cap | 81.22M |
| Revenue (ttm) | 40,268 |
| Net Income (ttm) | -10.28M |
| Shares Out | 20.25M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,708 |
| Open | 3.91 |
| Previous Close | 3.95 |
| Day's Range | 4.01 - 4.39 |
| 52-Week Range | 3.71 - 16.52 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 22.00 (+448.6%) |
| Earnings Date | Nov 15, 2021 |
About MIRO
Miromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them. Miromatrix Medical Inc. has strategical partnerships with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. Miromatrix Medical ...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MIRO stock is "Strong Buy" and the 12-month stock price forecast is 22.00.
News
Miromatrix Submits Pre-IND Request to the FDA for Its External Liver Assist Product to Treat Acute Liver Failure
The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022 The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022
Miromatrix Reports Third Quarter 2021 Results
EDEN PRAIRIE, Minn., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to hel...
Miromatrix to Report Third Quarter 2021 Financial Results
EDEN PRAIRIE, Minn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to hel...
Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Animal
Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement in new therapies for acute and chronic liver failure ...
Miromatrix Medical Added to Russell Microcap® Index
EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita The bio...
Miromatrix Medical Announces Closing of Initial Public Offering
EDEN PRAIRIE, Minn., June 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantabl...
Miromatrix Medical Announces Pricing of Upsized Initial Public Offering
EDEN PRAIRIE, Minn., June 24, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantabl...